Neoadjuvant melanoma therapy is revolutionizing the clinical landscape for patients with stage III and IV resectable disease. Historically, surgeons and oncologists relied on upfront surgery followed by adjuvant treatment. However, recent evidence suggests that utilizing systemic therapy before surgical intervention offers significant immunological benefits. By exposing the immune system to the tumor in situ, these therapies generate a more robust anti-tumor response. This shift in timing significantly enhances patient outcomes and changes the standard of care globally.

The rationale behind neoadjuvant systemic therapy (NAST) rests on the presence of a larger tumor antigen load. Consequently, the immune system can identify and target malignant cells more effectively before they are removed surgically. This approach not only shrinks primary tumors but also addresses micrometastatic disease early in the treatment course. Therefore, patients often experience a higher pathological complete response, which correlates strongly with long-term survival.

Evidence Supporting Neoadjuvant Melanoma Therapy

Remarkable results from recent clinical trials validate this approach. For instance, the SWOG-S1801 trial demonstrated that neoadjuvant-adjuvant pembrolizumab achieved a 2-year event-free survival (EFS) rate of 72%. In contrast, the adjuvant-only group saw only 49% EFS. Additionally, the NADINA trial reported a 1-year EFS rate of 83.7% using a combination of ipilimumab and nivolumab. These findings suggest that dual-agent immunotherapy provides even greater protection against recurrence than monotherapy.

Incorporating NAST into routine practice promises substantial improvements for patients with advanced resectable melanoma. While monitoring for immune-related adverse events remains crucial, the safety profile of these regimens is generally acceptable. Clinicians should consider these protocols to maximize the chances of long-term remission. Furthermore, the early assessment of pathologic response allows for personalized treatment adjustments post-surgery.

What are the primary benefits of neoadjuvant systemic therapy?

Neoadjuvant therapy enhances the immune system's ability to recognize tumor antigens in situ, leading to improved event-free survival and higher pathological response rates.

How did the NADINA trial change melanoma management?

The NADINA trial showed that combining ipilimumab and nivolumab neoadjuvantly reached a 1-year EFS rate of 83.7%, significantly outperforming standard adjuvant nivolumab.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Reddish S et al. Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions. N Z Med J. 2026 Apr 17. doi: 10.26635/6965.7104. PMID: 41990381.

Patel SP, et al. Neoadjuvant–Adjuvant Pembrolizumab for Resectable Antigen-Driven Melanoma. N Engl J Med. 2023;388:813-823.

Blank CU, et al. Neoadjuvant Nivolumab plus Ipilimumab in Resectable Melanoma. N Engl J Med. 2024;390:2113-2124.